Table 1.
Patients´ demographic and clinical characteristics
| Characteristic | Value (n = 181) |
|---|---|
| Median age (range), years | 71.4 (62.2–79.0) |
| Gender, n (%) | |
| Male | 69 (38.1) |
| Female | 112 (61.9) |
| Race, n (%) | |
| Caucasian | 178 (98.3) |
| Asian | 3 (1.7) |
| Smoking history, n (%) | |
| Former smoker | 53 (30.3) |
| Current smoker | 26 (14.9) |
| Never smoker | 96 (54.9) |
| ECOG PS at diagnosis of advanced disease, n (%) | |
| 0 | 46 (27.7) |
| 1 | 87 (52.4) |
| 2 | 26 (15.7) |
| 3 | 7 (8.1) |
| Tumor histology, n (%) | |
| Adenocarcinoma | 161 (89.0) |
| Squamous cell carcinoma | 9 (5.0) |
| Large cell carcinoma | 5 (2.8) |
| Adenosquamous cell carcinoma | 2 (1.1) |
| Carcinoma NOS | 4 (2.2) |
| Clinical stage at diagnosis, n (%) | |
| IIIA | 8 (4.4) |
| IIIB | 7 (3.9) |
| IV | 159 (87.8) |
| Othera | 7 (4) |
| Median number of metastatic sites (range) | 2.0 (1.0–3.0) |
| Metastases location, n (%)b | |
| Lung | 80 (45.7) |
| Bone | 75 (42.9) |
| Pleura | 50 (28.6) |
| Lymph nodes | 45 (25.7) |
| Pleural effusion | 30 (17.1) |
| CNS | 25 (14.3) |
| Liver | 25 (14.3) |
CNS Central nervous system, ECOG PS Eastern Cooperative Oncology Group Performance Status, NOS Not otherwise specified
aOther clinical stages included: IA (one patient), IIA (5 patients) and IIB (one patient), bMetastatic locations presented in > 10% of patients